Vnitr Lek 2025, 71(4):213-217 | DOI: 10.36290/vnl.2025.039

Up-to-date therapy of interstitial lung processes

Martina Šterclová

Pneumologická klinika 2. LF UK a FN Motol, Praha

Pneumologická klinika 1. LF UK a FN Motol, Praha

In recent years, attention has been paid to patients with connective tissue diseases and interstitial lung disease (ILD). This is reflected in the number of recently published guidelines dealing with this issue. Most of them evaluate the effect of already known molecules on the management of ILDs. During 2024, no clinical study was published that would enrich the portfolio of treatment options with a new molecule. Guidelines for the management and treatment of pulmonary alveolar proteinosis were recently published. It turns out that in patients with idiopathic pulmonary fibrosis who suffer acute exacerbation, treatment with high doses of corticosteroids can be considered more harmful than beneficial to the patient. Home oxygen therapy should continue to be reserved only for patients with ILD who meet the indication criteria for this therapy. The effect on alleviating exertional dyspnea in the daily life of patients has not been proven. Similarly, the benefit of opioid treatment to alleviate symptoms has not been proven. National guidelines dedicated to this issue are gradually updated and are available on the website of Czech Pneumological and Phthiseological Society.

Keywords: interstitial lung disease, connective tissue disease, pulmonary alveolar proteinosis, vasculitis.

Accepted: June 3, 2025; Published: June 19, 2025  Show citation